Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report
Authors:
Open Access
- 1 February 2022
- journal article
- abstracts
- Published by Springer Nature in AAPS Open
- Vol. 8 (1) , 1-7
Abstract
This conference report summarized a full-day workshop, “best practices for the development and fit-for-purpose validation of biomarker methods,” which was held prior to the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 Congress, San Antonio, TX, November 2019. The purpose of the workshop was to bring together thought leaders in biomarker assay development in order to identify which assay parameters and key statistical measures need to be considered when developing a biomarker assay. A diverse group of more than 40 scientists participated in the workshop. The workshop and subsequent working dinner stimulated robust discussion. While a consensus on best practices was not achieved, some common themes and major points to consider for biomarker assay development have been identified and agreed on. The focus of this conference report is to summarize the presentations and discussions which occurred at the workshop. Biomarker assay validation is a complex and an evolving area with discussions ongoing.Keywords
This publication has 17 references indexed in Scilit:
- The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic DirectionClinical Pharmacology & Therapeutics, 2019
- Biomarker Assay ValidationBioanalysis, 2018
- 11th GCC Closed Forum: Cumulative Stability; Matrix Stability; Immunogenicity assays; Laboratory Manuals; Biosimilars; Chiral methods; Hybrid LBA/LCMS Assays; Fit-for-Purpose Validation; China Food and Drug Administration Bioanalytical Method ValidationBioanalysis, 2018
- Recommendations for Selection and Characterization of Protein Biomarker Assay Calibrator MaterialThe AAPS Journal, 2017
- Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?npj Precision Oncology, 2017
- Recommendations for Clinical Biomarker Specimen Preservation and Stability AssessmentsBioanalysis, 2017
- Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug DevelopmentThe AAPS Journal, 2015
- CSF beta‐amyloid 1–42 – what are we measuring in Alzheimer's disease?Annals of Clinical and Translational Neurology, 2014
- Fit-for-Purpose Method Development and Validation for Successful Biomarker MeasurementPharmaceutical Research, 2006
- Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference ReportPharmaceutical Research, 2005